Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
144
resultados
Última actualización
06/09/2026 [07:00:00]
Resumen de: US20260260730A1
A method of administering insulin includes receiving scheduled glucose time intervals and obtaining glucose data of a patient that includes glucose measurements, glucose times, and insulin dosages previously administered by the patient. The method also includes applying a set of filters to identify which of the glucose measurements associated with at least one of the scheduled time intervals are usable and which of the glucose measurements associated with the at least one scheduled time interval are unusable. The method also includes aggregating the glucose measurements associated with the at least one scheduled time interval identified as usable to determine a representative aggregate glucose measurement and determining a next recommended insulin dosage for the patient based on the representative aggregate glucose measurement and the insulin dosages previously administered by the patient.
Resumen de: US20260258141A1
Provided are anti-IGF1R (insulin-like growth factor 1 receptor) antibodies, antigen-binding fragments, and the uses thereof.
Resumen de: US20260257014A1
Disclosed herein are systems and methods incorporating an ambulatory infusion pump and a CGM. These systems that can include software and related methods to provide improved automated insulin delivery algorithms that enable the algorithms to safely continue delivering insulin for some time periods of missing or known inaccurate glucose values.
Resumen de: US20260258368A1
0000 Methods are provided for in vitro selection of metabolic selection of metabolically selectable mammalian cells that don't require exogenous glucose and glutamine in culture. Such cells may be glycogen-storing mammalian cells, including without limitation hepatocytes. Metabolic selection provides an approach to rapidly kill non-selectable cells by withholding specific nutrients from the culture medium.
Resumen de: EP4800372A2
0001 A continuous glucose monitoring system may utilize electrode current (Isig) signals, Electrochemical Impedance Spectroscopy (EIS), and Vcntr values to optimize sensor glucose (SG) calculation in such a way as to enable reduction of the need for blood glucose (BG) calibration requests from users.
Resumen de: EP4799662A1
The invention discloses a method and system for postprandial insulin infusion based on identifiable feature of diabetic, acquiring a food image by an imaging mechanism, and analyzing the food image by the food image recognition model to obtain food data, retrieving a narrow insulin algorithm adapted to the patient's own identifiable features from the cluster of narrow insulin algorithms according to the identifiable features of the patient, for calculation of insulin infusion amount during meals, compared to the preset insulin algorithm, the narrow insulin algorithm is more applicable to the physiological characteristics and living habit of the patient, the calculated postprandial insulin infusion amount is more accurate, and is beneficial for the treatment of diabetic.
Resumen de: EP4800695A2
0001 Techniques for performing application-layer security and communication over primary invitation channels are disclosed. In certain embodiments, analyte data is obtained from an analyte sensor electrically coupled to a sensor electronics module of an analyte sensor system. A secret key is established with a display device over one or more primary invitation channels. The analyte data is encrypted using the secret key. The encrypted analyte data is broadcast over the one or more primary invitation channels.
Resumen de: EP4800696A1
The present invention relates to a computer implemented training method for training a first artificial intelligence agent for glycemic control of a patient and also relates to a computer implemented method of determining an insulin dose value for a patient next to administer and for administration by an insulin administration device based on a treatment algorithm comprising a first artificial intelligence agent.
Resumen de: EP4800534A2
The subject matter disclosed herein provides methods for presenting glucose level data. Glucose data for a patient may be received. A current glucose level and a rate of change of the current glucose level may be determined based on the received glucose data. A first interface may be displayed on a screen of a device. The first interface may include a unitary icon. The unitary icon may display the current glucose level and a visualization of the rate of change. Related apparatus, systems, techniques, and articles are also described.
Resumen de: US12721549B1
0000 A wearable medical monitoring device comprises a microneedle array configured to extract interstitial or capillary fluid from a user, biosensors configured to detect biomarkers including glucose and complete blood count parameters such as white blood cells, red blood cells, hemoglobin, hematocrit, and platelet count, a microprocessor configured to generate biomarker data from biosensor signals, and a wireless communication module configured to transmit biomarker data to a user device for forwarding to a server. The server analyzes biomarker data using machine learning models including time-series forecasting, anomaly detection, classification, and ensemble models to detect health condition anomalies and generate alerts. The machine learning models are updated via federated learning using anonymized data. The server establishes personalized baseline values and dynamically adjusts alert thresholds based on user-specific factors and environmental context.
Resumen de: MA70860A1
The invention concerns a smart ring designed to monitor the user's vital parameters and predict the risk of developing acute coronary syndrome (ACS). This watch incorporates advanced signal processing techniques and sophisticated algorithms to analyze heart rate variability as well as total cholesterol, blood glucose and blood pressure levels associated with acute coronary events. The vital data is sent to a server via an NB-IoT communication module, and visualized using a web interface. An integrated artificial intelligence model continuously analyzes the processed data to identify patterns indicative of ACS. If a high risk of ACS is detected, the ring emits visual and audible alerts, prompting the user to seek immediate medical attention. In addition, a user interface offers the possibility of viewing data and forecasts in real time, enabling continuous, proactive monitoring. This invention enables early detection of ACS thanks to improved analysis of vital parameters and the use of artificial intelligence for continuous real-time monitoring, thus improving the safety of preventive medical measures and the well-being of the user.
Resumen de: AU2025213042A1
Disclosed herein is a healthcare management system and method utilizing machine learning based predictive analytics to improve patient adherence rates for chronic care management (e.g., diabetes). An example system may include a computing device configured to establish a customer analytical record to synthetize over a plurality of selected attributes to form a patient centric view of patient behaviors, attitude, characteristics based upon data related to chronic disease state management and social determinants of health, consumer experience to determine, using a predictive artificial intelligence model, a patient's predictive adherence for next 1-3 months, and determine tailored intervention plans to engage patients for continuing adherence.
Resumen de: US20260253354A1
A system and method for interactive three-dimensional visualization of physiological stress effects on the human body uses biomarker correlation algorithms to determine physiological responses to physical trauma and toxic stress events. The system receives stress event data, calculates biomarker levels including cortisol, blood pressure, blood sugar, and inflammatory markers, and identifies affected organ systems including cardiovascular, nervous, endocrine, digestive, immune, and reproductive systems. Three-dimensional anatomical models are modified with visual characteristics depicting stress-induced changes based on the biomarker data, including color alterations, geometric deformations, and animated effects. A temporal progression interface enables visualization of immediate, short-term, and long-term physiological effects. Spatial audio synchronized with visual animations provides immersive auditory feedback. Cross-platform rendering modules optimize visualization for mobile devices, desktop computers, tablets, virtual reality headsets, and augmented reality glasses. The system provides for real-time interactive manipulation of anatomical visualizations, particularly for pediatric toxic stress education related to corporal punishment.
Resumen de: US20260248422A1
A personal electronic device and wearable sensing system includes one or more dermal-contact electrochemical sensors integrated into one or more skin-contact surfaces of the electronic device, wearable, accessory, or interactive electronic system. The electrochemical sensors obtain measurements indicative of one or more analyte classes associated with a user. One or more additional sensors obtain non-electrochemical measurements associated with the user. A sensor-fusion module derives electrochemical and non-electrochemical features and generates a unified state estimate. One or more inference modules determine a user-state output based on the unified state estimate and a comparison of electrochemical-derived information, or features derived therefrom, to an individualized baseline reference profile associated with the user. In some embodiments, the analyte classes include endogenous physiological markers including glucose-related markers, exogenous exposure analytes, or both. In some embodiments, a credential derived from the individualized baseline reference profile is portable across multiple authorized devices within a trusted ecosystem.
Resumen de: US20260248419A1
Provided is a blood glucose data management method including identifying first blood glucose data based on a blood glucose sensor, identifying a verification dataset corresponding to the first blood glucose data, estimating whether at least a portion of the blood glucose sensor is detached from a user's body based on a comparison between a pattern corresponding to the verification dataset and a reference pattern, and suspending output of the first blood glucose data if detachment is estimated.
Resumen de: WO2026177370A1
A method for adjusting insulin comprises the steps of: an analysis apparatus acquiring carbohydrate intake data, continuous blood glucose data, and insulin administration data; the analysis apparatus determining a meal time point on the basis of the continuous blood glucose data; the analysis apparatus setting, as a pre-meal blood glucose value, a minimum blood glucose value during a preset period before the meal time point; and the analysis apparatus determining, on the basis of the pre-meal blood glucose value, the amount of insulin to be injected.
Resumen de: AU2025224752A1
Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and/or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.
Resumen de: US20260249003A1
The disclosed relates to an insulin syringe replacement system for an insulin pump. The system comprises: a control unit for controlling the operation of the insulin pump; an operation unit for performing an initialization setting operation when an insulin syringe is replaced under the control of the control unit; and a battery unit for supplying power to the control unit and the operation unit; a housing unit for mounting the insulin syringe; and a sensor unit for confirming whether a stopper of the insulin syringe mounted on the housing unit is coupled and notifying the control unit of the confirmation, wherein the control unit controls the operation unit to perform the initialization setting operation only after receiving the confirmation from the sensor unit that the stopper of the insulin syringe mounted on the housing unit is coupled.
Resumen de: US20260249007A1
0000 A technique for treating diabetes that recognizes patient insulin sensitivity is a time-varying physiological parameter. The described techniques for treating diabetes include measuring interstitial fluid glucose concentration, reading insulin delivery data, determining patient insulin sensitivity based on the interstitial fluid glucose concentration and insulin delivery data, and a time-varying physiological parameter, and dispensing an insulin dose from an insulin delivery device based on the determined patient insulin sensitivity.
Resumen de: AU2026214068A1
A stool resuspension solution comprising a hemoglobin stabilization reagent is provided. In some embodiments, the hemoglobin stabilization reagent may be an osmolyte, a polyvalent cation, a sugar or polysaccharide and, optionally, a polyvalent cation, a protoporphyrin,or an HRP stabilization component and, optionally, a polyvalent cation. A method of stabilizing hemoglobin in a stool sample in the solution is also provided, as well as a sample collection device containing the solution. ug u g
Resumen de: US20260253702A1
The system according to the embodiment comprises a collection unit, an analysis unit, and a notification unit. The collection unit collects vital data. The analysis unit analyzes data collected by the collection unit and predicts changes in blood glucose levels. The notification unit notifies the timing of insulin injection based on the changes in blood glucose levels predicted by the analysis unit. The notification unit notifies the user and contacts when hypoglycemia is detected.
Resumen de: WO2026175096A1
Provided in the present application are a blood glucose monitoring method and a related apparatus. In the method, the blood glucose level at a first moment can be acquired on the basis of a glucose concentration in interstitial fluid at the first moment, a glucose concentration in the interstitial fluid within a time period before the first moment and a glucose concentration in the interstitial fluid within a time period after the first moment. In the present application, the glucose concentration in the interstitial fluid within the time period after the first moment is taken into consideration, and an additional time period is provided for the diffusion of glucose between the interstitial fluid and blood; therefore, when the blood glucose level drastically changes, the glucose concentration in the interstitial fluid more closely approximates the blood glucose level, and thus the accuracy of blood glucose monitoring can be improved.
Resumen de: EP4796031A2
The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation can occur in a stabilized state, and thereby allowing more accurate blood glucose monitoring.
Resumen de: EP4796158A1
0001 L'invention concerne un ensemble (1) d'administration d'un médicament liquide, de préférence de l'insuline, comprenant une pompe (10) de perfusion comprenant un réservoir (11) pour stocker le médicament liquide, et un premier connecteur (13) comprenant un taraudage (14), en communication fluidique avec le réservoir (11), et un cathéter (20) comprenant un tuyau flexible (21) équipé d'un second connecteur (23) comprenant un filetage (24) complémentaire du taraudage (14) du premier connecteur (13) de manière à pouvoir coupler par vissage les premier et second connecteurs (13, 23), l'un à l'autre, et ainsi raccorder fluidiquement le cathéter (20) à la pompe (10). Le couplage par vissage des premier et second connecteurs (13, 23), l'un à l'autre, comprend un déplacement en rotation (R) relatif de l'un par rapport à l'autre, selon un angle de rotation compris entre 100° et 200°.
Nº publicación: EP4796034A2 26/08/2026
Solicitante:
I SENS INC [KR]
i-Sens, Inc.
Resumen de: EP4796034A2
0001 The present disclosure relates to a body-attachable unit for continuously measuring blood glucose. As the body-attachable unit is manufactured to be assembled in an applicator, additional effort is minimized such that the body-attachable unit can be attached to the body by simply operating the applicator. In particular, since the body-attachable unit is provided with a wireless communication chip such that communication with an external terminal is possible, the body-attachable unit can be used simply and conveniently without additional work of connecting a separate transmitter, and thus can be maintained more easily. In addition, since the body-attachable unit is operated by an operation of a user after being attached to the body, the start time of the operation can be adjusted to an appropriate time according to the needs of the user. Accordingly, the body-attachable unit can be operated in a stabilized state, thereby allowing for more accurate blood glucose measurement.
BOPI
Sede Electrónica
